N

Navamedic ASA
OSE:NAVA

Watchlist Manager
Navamedic ASA
OSE:NAVA
Watchlist
Price: 21.5 NOK Market Closed
Market Cap: 379.7m NOK
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one NAVA stock under the Base Case scenario is 63.59 NOK. Compared to the current market price of 21.5 NOK, Navamedic ASA is Undervalued by 66%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NAVA Relative Value
Base Case
63.59 NOK
Undervaluation 66%
Relative Value
Price
N
Worst Case
Base Case
Best Case

Valuation Multiples

0.7
P/S
P/S
Price to Sales
0.7
vs History
93
vs Industry
76
Median 3Y
1.3
Median 5Y
1.4
Industry
2.5
Forward
0.7
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
0
Median 3Y
21.4
Median 5Y
11.2
Industry
21.5
Forward
29.1
More Details
9.6
P/OCF
P/OCF
Price to OCF
9.6
vs History
61
vs Industry
37
Median 3Y
33.5
Median 5Y
16.5
Industry
16.6
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
29
Median 3Y
11.1
Median 5Y
7.3
Industry
24.9
More Details
1.8
P/B
P/B
Price to Book Value
1.8
vs History
88
vs Industry
45
Median 3Y
2.8
Median 5Y
2.6
Industry
2.1
More Details
0.8
EV/S
EV/S
Enterprise Value to Sales
0.8
vs History
96
vs Industry
76
Median 3Y
1.4
Median 5Y
1.4
Industry
2.7
Forward
0.7
More Details
1.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
1.9
vs History
96
vs Industry
70
Median 3Y
3.5
Median 5Y
3.7
Industry
5.2
More Details
5.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
5.4
vs History
80
vs Industry
27
Median 3Y
13.1
Median 5Y
13.5
Industry
12.8
Forward
7.7
More Details
11.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
11.5
vs History
71
vs Industry
32
Median 3Y
15.9
Median 5Y
14.5
Industry
16.3
Forward
10.7
More Details
10.5
EV/OCF
EV/OCF
Enterprise Value to OCF
10.5
vs History
65
vs Industry
36
Median 3Y
32.3
Median 5Y
16
Industry
14.9
More Details
11.5
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
11.5
vs History
50
vs Industry
30
Median 3Y
17
Median 5Y
11.7
Industry
17.9
More Details
1.1
EV/IC
EV/IC
Enterprise Value to IC
1.1
vs History
96
vs Industry
54
Median 3Y
1.7
Median 5Y
1.8
Industry
1.9
More Details

Multiples Across Competitors

NAVA Competitors Multiples
Navamedic ASA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
NO
Navamedic ASA
OSE:NAVA
379.8m NOK 0.7 -33.4 5.4 11.5
US
Eli Lilly and Co
NYSE:LLY
777B USD 15.9 70 37.5 41
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
378.3B USD 4.2 17.4 12.7 16.6
DK
Novo Nordisk A/S
CSE:NOVO B
2.3T DKK 7.6 21.9 15.1 17.3
CH
Roche Holding AG
SIX:ROG
214.6B CHF 3.5 25.9 9.7 11.4
CH
Novartis AG
SIX:NOVN
190.6B CHF 4.4 18.3 10.8 14.4
UK
AstraZeneca PLC
LSE:AZN
170.3B GBP 4.2 29.9 131.4 198.2
US
Merck & Co Inc
NYSE:MRK
206.3B USD 3.2 11.9 8.8 10.7
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
140.4B USD 2.2 17.8 7.6 10.7
P/E Multiple
Earnings Growth PEG
NO
N
Navamedic ASA
OSE:NAVA
Average P/E: 26.6
Negative Multiple: -33.4 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
70
50%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.4
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
21.9
18%
1.2
CH
Roche Holding AG
SIX:ROG
25.9
32%
0.8
CH
Novartis AG
SIX:NOVN
18.3
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
29.9
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.9
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.8
31%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NO
N
Navamedic ASA
OSE:NAVA
Average EV/EBITDA: 395.2
5.4
8%
0.7
US
Eli Lilly and Co
NYSE:LLY
37.5
30%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.7
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
15.1
13%
1.2
CH
Roche Holding AG
SIX:ROG
9.7
5%
1.9
CH
Novartis AG
SIX:NOVN
10.8
5%
2.2
UK
AstraZeneca PLC
LSE:AZN
131.4
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.8
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
2%
3.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NO
N
Navamedic ASA
OSE:NAVA
Average EV/EBIT: 1 699
11.5
33%
0.3
US
Eli Lilly and Co
NYSE:LLY
41
32%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.6
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
17.3
14%
1.2
CH
Roche Holding AG
SIX:ROG
11.4
6%
1.9
CH
Novartis AG
SIX:NOVN
14.4
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
198.2
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.7
11%
1
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.7
10%
1.1

See Also

Summary
NAVA intrinsic value, competitors valuation, and company profile.
DCF Valuation
NAVA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NAVA stock valuation using valuation multiples.
Wall Street Estimates
NAVA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NAVA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 261,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.